Navigation Links
Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial

sal hormone therapy and resulted in significantly fewer women using these products," said Isaac Cohen, CEO of Bionovo. "For this reason, it is important for us to find safer alternatives for treating menopausal symptoms. The favorable dose response trend signals that MF101 may become a clear alternative to traditional postmenopausal hormone therapy for relief of vasomotor symptoms. We are excited by the prospect of moving forward with the development of a product that could potentially have such broad reach and positively affect the quality of life for millions of women and their loved ones. This first Phase 2 trial conducted by Bionovo serves as a proof of our drug development strategy and we look forward to advancing MF101 into registration trials."

About MF101

MF101 is an estrogen receptor (ER) beta selective drug developed as an alternative to postmenopausal hormone products currently on the market, which are both ER beta and ER alpha agonists that have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with ER alpha activation and that ER beta blocks the growth promoting effects on breast cancer cells. Bionovo recognized the opportunity to commercialize a product that would be equally effective, with an improved safety profile compared to traditional hormone therapy. The clinical trial results have been evaluated by an independent Data and Safety Monitoring Board and the drug candidate has passed through a standard two-phase examination for safety.

Bionovo, Inc.

Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:10/30/2014)... 30, 2014   NxStage® Kidney Care, Inc ., a ... is proud to host the grand opening ceremony of its ... W. 16 th Street on November 20, 2014 from ... trained medical staff who are committed to providing patients with ... benefits made possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... Oct. 30, 2014 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... release third quarter 2014 financial results on Wednesday, November ... The Company,s management will hold a conference call at ... which is 8:30 p.m., Beijing Time on November 6, ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3China Biologic to Report Third Quarter 2014 Financial Results 2
... Reportlinker.com announces that a new market research ... European Markets for Dental Bone Graft Substitutes, ... http://www.reportlinker.com/p0339837/European-Markets-for-Dental-Bone-Graft-Substitutes-Dental-Membranes-and-Tissue-Engineering-2011.html In ... graft substitutes and other biomaterials grew by 4.4% ...
... (Nasdaq: VRNM ), a pioneer in the ... today announced key 2010 accomplishments and 2011 Company ... a significant year of transition for Verenium as we ... building the next leading industrial enzymes company," said Carlos ...
Cached Medicine Technology:Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 2Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 3Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 4Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 5Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 6Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 7Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 8Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 9Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 10Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 11Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 12Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 13Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 14Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 15Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 16Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 17Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 18Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 19Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011 20Verenium Announces 2010 Business Update and Outlook for 2011 2Verenium Announces 2010 Business Update and Outlook for 2011 3Verenium Announces 2010 Business Update and Outlook for 2011 4Verenium Announces 2010 Business Update and Outlook for 2011 5
(Date:10/30/2014)... Five months after their expansion, the AV ... branding and a website to accompany their recent change ... promotion to name partner earlier this year, Hodgkinson Street ... name and better reflect their combined litigation expertise. As ... to implement new branding reflects Hodgkinson Street Mepham’s collaborative ...
(Date:10/30/2014)... 2014 Radio listeners who indicate use ... the impact of traditional radio commercials and have overwhelmingly ... to influence a purchasing decision. , Those are some ... conducted by radio marketing company CRN International. The research ... results of respondents who indicated they have purchased or ...
(Date:10/30/2014)... Dennis Thompson HealthDay ... The Ebola outbreak in Liberia -- one of three West ... World Health Organization officials said Wednesday. Dr. Bruce Aylward, ... the number of burials in Liberia and no increase in ... global push to tame the epidemic may be making some ...
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... California (PRWEB) October 30, 2014 REV'D ... bars are now available through a unique service called, ... site designed to empower the everyday athlete. The Feed ... best athletes and created a system to pass that ... to see REV’D® is now available on The Feed!” ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3
... dysfunctions- painful intercourse, sexual dissatisfaction and a multitude ... the patients and their doctors communicated better, most ... all women, as they go through menopause, will ... known as genital atrophy. ,This results in ...
... back with a vengeance. The killer disease of the past is ... partner in its destructive mission. Full-blown cases of AIDS coupled with ... in Africa alone. What is alarming is that the death rate ... no signs of the destruction slowing down. ,Health experts argue ...
... deaths due to asthma can be prevented if the ... disease. According to WHO, around 150 million people suffer ... due to the disease every year. Asthma is a ... characterized by sudden recurring attacks of labored breathing, chest ...
... that wound healing in depressed people is four times slower ... a place in the latest issue of the journal, “Psychosomatic ... on the rate of wound healing, according to the researchers. ... the immune system, which may keep a wound from healing ...
... injure the donor, it is now established without doubt that a ... person needing it. And the good news is that the donor ... his/her liver. ,Donation of a piece of the liver's right ... It is increasingly being performed in the West where the demand ...
... for the treatment of cancer has nearly,doubled during ... survey of pharmaceutical,companies.,Currently, 170 pharmaceutical and biotechnology firms ... treatment of various,cancers, up from 215 in 1995. ... and chemotherapy. For lung cancer, the leading cause ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: